Clinical Scorecard: FDA Greenlights Repeat Use of Glaukos’ iDose® TR
At a Glance
| Category | Detail |
|---|---|
| Condition | Glaucoma |
| Key Mechanisms | Continuous delivery of travoprost via intracameral implant |
| Target Population | Patients with glaucoma maintaining healthy cornea |
| Care Setting | Ophthalmology |
Key Highlights
- FDA approved repeat administration of iDose TR
- Designed for long-duration therapeutic delivery
- No significant corneal endothelial cell loss observed in studies
- Safe and well-tolerated second administration confirmed
- Enhances treatment flexibility for glaucoma management
Guideline-Based Recommendations
Diagnosis
- Assess corneal endothelial cell density before re-administration
Management
- Consider repeat use of iDose TR for patients with stable corneal health
Monitoring & Follow-up
- Monitor corneal health and endothelial cell density post-treatment
Risks
- Potential for corneal endothelial cell loss if corneal health is compromised
Patient & Prescribing Data
Glaucoma patients with healthy corneas
iDose TR provides sustained therapeutic levels, reducing need for topical medications
Clinical Best Practices
- Evaluate corneal health regularly in glaucoma patients
- Educate patients on the benefits of sustained therapy with iDose TR
- Document treatment outcomes and any adverse effects during follow-up
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
